RSS FDA Accepts Astellas Pharma's Revised SNDA For IZERVAY In Geographic Atrophy Treatment

Currently reading:
 RSS FDA Accepts Astellas Pharma's Revised SNDA For IZERVAY In Geographic Atrophy Treatment

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
10,945
Likes
1,923
Credits
33,627©
Cash
0$
Astellas Pharma Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted the revised supplemental New Drug Application (sNDA) for IZERVAY (avacincaptad pegol intravitreal solution). This application pertains to the treatment of geographic atrophy (GA) associated with age-related macular degeneration (AMD). The resubmission follows the FDA's Complete Response Letter (CRL) received in November 2024.

Astellas refilled the application after a meeting with the FDA on December 20, 2024. It has been designated as a Class 1 resubmission, which entails a 60-day review period. The expected decision date is set for February 26, 2025.

Initially, IZERVAY received FDA approval on August 4, 2023, for treating geographic atrophy related to macular degeneration. The current sNDA aims to incorporate positive two-year data from the GATHER2 Phase 3 clinical trial into the IZERVAY U.S. Prescribing Information.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips

Similar threads

Top Bottom